2024
Optimizing public-private partnerships to support clinical cancer research
Herbst R, Blumenthal G, Khleif S, Lippman S, Meropol N, Rosati K, Shulman L, Smith H, Wang M, Winn R, Schilsky R. Optimizing public-private partnerships to support clinical cancer research. Journal Of The National Cancer Institute 2024, djae279. PMID: 39666955, DOI: 10.1093/jnci/djae279.Peer-Reviewed Original ResearchClinical cancer researchNational Cancer Policy ForumPublic-private partnershipEquitable care deliveryCancer researchCare deliveryEfficient drug developmentImplementation of public-private partnershipPromote collaborationTherapeutic innovationsClinical applicationPartnershipPolicy forumsDrug developmentNonprofit organizations
2012
The Microculture-Kinetic (MiCK) Assay: The Role of a Drug-Induced Apoptosis Assay in Drug Development and Clinical Care
Bosserman L, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S, Raptis A, Hallquist A, Perree M, Rajurkar S, Karimi M, Rogers K, Davidson D, Willis C, Penalver M, Homesley H, Burrell M, Garrett A, Rutledge J, Chernick M, Presant CA. The Microculture-Kinetic (MiCK) Assay: The Role of a Drug-Induced Apoptosis Assay in Drug Development and Clinical Care. Cancer Research 2012, 72: 3901-3905. PMID: 22865459, DOI: 10.1158/0008-5472.can-12-0681.Peer-Reviewed Original ResearchConceptsHigh response rateLonger survivalClinical trialsResponse rateGroup of patientsBlinded clinical trialEpithelial ovarian cancerApoptosis assaysAcute myelocytic leukemiaUnblinded clinical trialDrug developmentGeneric drug useMultiple tumor typesEfficient drug developmentCombination therapyOvarian cancerMyelocytic leukemiaClinical careTumor typesDrug useClinical therapyClinical useMolecular biomarkersDrug approvalHigher apoptosis